Cannovation Brings on New Chief Scientific Officer as We Divide the Organization into 3 Divisions.

Cannovation is pleased to announce the new changes within our organization as of January 1, 2025. We have created 3 clinical research (CRO) service divisions within Cannovation focused on the following:

1. Traditional drug development including rare diseases, medical devices, and animal health.

2. Psychedelic-based drug and product development.

3. Cannabis-derived novel therapeutics and products.

   
   

These divisions were formed based on the market demand, regulatory demands in these specific areas, and the specialized services required in each of these areas for our clients. 

Secondly, we are pleased to announce the addition of Dr. James Linden, Ph.D., to the position of Chief Scientific Officer of Cannovation Clinical Research Partners, LLC (CCRP). He will lead Cannovation’s strategic direction along with myself to deliver expertise and services for pre-clinical and clinical trials (Phases I-IV), regulatory strategies, and go-to-market solutions with a focus on addressing neuropsychiatric conditions such as PTSD, anxiety, depression, addiction, and end-of-life distress. 

Cannovation Clinical Research Partners, LLC. is the first full-service consulting firm specializing in research, development, and commercialization of cannabinoid and psychedelic therapeutics. We partner with pharmaceutical companies, universities, and DEA-licensed researchers to accelerate the path to market for innovative prescription and non-prescription therapeutics in the U.S.

Our expertise includes pre-clinical and clinical trials (Phases I-IV), regulatory strategies, and go-to-market solutions, with a focus on addressing neuropsychiatric conditions such as PTSD, anxiety, depression, addiction, and end-of-life distress. We also support companies developing novel cannabis-based therapeutics like cannabinoids (THC, CBD, CBG).

What Sets Us Apart:

1.     Expertise across the entire product lifecycle, from pre-clinical to commercialization.

2.     Three core service areas:

• Innovative therapeutics for rare diseases, medical devices, and animal health.

• Psychedelic-based drug development.

• Cannabis-derived therapeutics.

Key Services We Offer:

• Business Planning & Market Strategy

• Clinical Trials (Pre-Clinical & Clinical)

• Regulatory Pathways & Pre-IND Guidance

• Supply Chain & Material Sourcing

• Commercial Strategies

We look forward to 2025 and working with our clients and partners to ensure the delivery of the “Best in Class” CRO services for drug and product development, commercialization, and innovation in the U.S. and for non-U.S. based clients.